LL-37 Peptide: The Antimicrobial That Cuts Both Ways

LL-37 is the only cathelicidin antimicrobial peptide produced by the human body. It kills bacteria, fungi, and viruses on contact. It accelerates wound healing. It modulates inflammation in both directions.

That last point is the problem. For eczema patients, LL-37 deficiency leaves skin vulnerable to chronic infection. For psoriasis patients, LL-37 overexpression triggers the autoimmune cascade itself. Whether this peptide helps or harms depends entirely on which autoimmune condition you have.

What Is LL-37?

LL-37 is a 37-amino-acid peptide that begins with two leucine residues (hence the name). It is cleaved from its precursor protein hCAP18 by proteinase 3, and it is produced by neutrophils, macrophages, keratinocytes, and epithelial cells throughout the body.

The peptide operates across multiple tissue systems. Skin, gastrointestinal tract, respiratory tract, and urogenital tract all express LL-37 as part of their innate immune defense. When a pathogen breaches a barrier surface, LL-37 is among the first molecules deployed.

One detail matters more than any other for autoimmune patients: the gene encoding LL-37 (CAMP) is a direct transcriptional target of the vitamin D receptor. Vitamin D status directly controls how much LL-37 your body produces. This connection explains part of why vitamin D supplementation improves outcomes across multiple autoimmune conditions.

How LL-37 Works

LL-37 is not a single-function molecule. It operates through at least six distinct mechanisms.

Antimicrobial action. LL-37 disrupts microbial cell membranes by inserting into their lipid bilayers and forming pores. Published data documents activity against at least 38 bacterial species, 16 fungi, and 16 viruses. The killing is rapid and direct.

Biofilm disruption. Bacterial biofilms are organized microbial communities that resist antibiotics and immune clearance. LL-37 penetrates and dismantles these structures. This property is relevant to chronic infections and, as discussed below, to Crohn's disease pathology.

Endotoxin neutralization. LL-37 binds lipopolysaccharide (LPS), the endotoxin released by gram-negative bacteria. LPS drives systemic inflammation when it crosses the gut barrier. By neutralizing LPS before it activates immune cells, LL-37 reduces downstream inflammatory signaling.

Wound healing. LL-37 promotes keratinocyte migration to wound edges and stimulates angiogenesis (new blood vessel formation) at injury sites. It also reduces fibrosis during repair. For autoimmune patients on immunosuppressants with impaired healing, this mechanism is clinically relevant.

Immune cell recruitment. LL-37 acts as a chemotactic signal, drawing neutrophils, monocytes, and T cells to sites of infection or tissue damage.

Dual immunomodulation. Here is where the complexity begins. LL-37 can suppress inflammation by inhibiting TLR4 signaling and reducing pro-inflammatory cytokine release. It can also amplify inflammation by activating plasmacytoid dendritic cells and triggering interferon production. The direction depends on context: what other molecules are present, what tissue the peptide is acting in, and whether self-DNA is available to form immune complexes.

The LL-37 Paradox in Autoimmune Disease

This paradox is the central fact about LL-37 that most patient-facing content fails to address. Blanket recommendations to "boost LL-37 for immune health" are dangerous for roughly half of autoimmune conditions.

When Low LL-37 Is the Problem: Eczema and Chronic Infections

Patients with atopic dermatitis produce insufficient LL-37 in their skin. Ong et al. established this in a landmark 2002 study published in the New England Journal of Medicine. Compared to psoriasis patients (who overexpress antimicrobial peptides), eczema patients showed markedly reduced LL-37 induction in lesional skin.

The clinical consequence is measurable. LL-37 deficiency leaves eczema skin vulnerable to Staphylococcus aureus colonization, herpes simplex (eczema herpeticum), and molluscum contagiosum. The chronic infection cycle perpetuates inflammation and barrier breakdown.

A 2009 study found enhanced LL-37 expression during active re-epithelialization in eczema lesions, suggesting the body attempts to upregulate production for repair. But baseline output remains insufficient. The deficit is structural, not transient.

The therapeutic logic follows directly: restore LL-37 levels. Vitamin D optimization (the CAMP gene is vitamin D-dependent) is the safest first step. Direct peptide supplementation is an emerging option with a strong mechanistic rationale but no completed RCTs.

When High LL-37 Is the Problem: Psoriasis and Cutaneous Lupus

In psoriasis, the situation reverses completely. LL-37 is overexpressed in lesional skin.

Lande et al. published the mechanism in Nature Medicine (2007). Damaged keratinocytes in psoriatic skin release fragments of self-DNA. LL-37 binds these DNA fragments and forms complexes. These LL-37/DNA complexes activate plasmacytoid dendritic cells through Toll-like receptor 9 (TLR9), triggering massive interferon-alpha production. Interferon-alpha then drives the Th17 inflammatory cascade that defines psoriasis.

LL-37 in psoriasis is not a defender. It is a trigger. The peptide converts harmless self-DNA debris into an autoimmune signal.

The same mechanism operates in cutaneous lupus erythematosus. LL-37/DNA and LL-37/RNA complexes activate the same TLR9 and TLR7 pathways, producing the interferon signature characteristic of lupus skin disease.

Supplemental LL-37 is contraindicated in psoriasis and cutaneous lupus. This is not a gray area. Adding more LL-37 to a system where overexpression is already driving disease progression risks amplifying the autoimmune cascade.

Evidence by Condition

Eczema / Atopic Dermatitis (Grade B)

The evidence for LL-37 deficiency in eczema is strong. The NEJM study (Ong et al. 2002) is the foundation: eczema patients have impaired antimicrobial peptide production in skin, and this deficiency correlates with increased skin infection rates.

Vitamin D supplementation improves eczema outcomes in multiple trials, and LL-37 induction is one proposed mechanism. The VITAL trial (2022) showed a 22% reduction in autoimmune disease incidence with vitamin D3, though it did not measure LL-37 directly.

No RCT has tested LL-37 peptide supplementation specifically in eczema. The evidence grade is B: strong mechanistic and observational data, clear deficiency documented, but the therapeutic intervention (exogenous LL-37) has not been validated in a controlled trial. Vitamin D optimization remains the safer, better-supported strategy for improving LL-37 status in eczema.

Crohn's Disease (Grade C+)

LL-37 is expressed throughout the gastrointestinal epithelium as part of the gut's innate antimicrobial defense. In Crohn's disease, impaired innate immunity against adherent-invasive E. coli (AIEC) is a recognized pathological feature. AIEC forms biofilms in the ileum that perpetuate inflammation.

LL-37's biofilm-disrupting properties make it a theoretically attractive intervention for Crohn's. If the peptide can dismantle AIEC biofilms, it could address one of the upstream drivers of ileal inflammation.

The indirect evidence is supportive: vitamin D (which induces LL-37) improves Crohn's outcomes in clinical studies. Crohn's disease supplements with established evidence include vitamin D, omega-3, and curcumin, all of which may partially work through antimicrobial peptide induction.

No Crohn's-specific LL-37 clinical studies exist. The grade is C+ because the mechanistic rationale is strong and condition-specific, but clinical validation is absent.

Chronic Wounds and Skin Healing (Grade B)

Multiple preclinical studies demonstrate that LL-37 accelerates wound closure. The peptide promotes keratinocyte migration to wound edges, stimulates angiogenesis for blood supply, and reduces excessive fibrosis.

For autoimmune patients on long-term immunosuppressants (methotrexate, biologics, corticosteroids), impaired wound healing is a common clinical problem. LL-37's wound-healing properties address a real unmet need in this population.

The evidence remains preclinical. No human wound-healing trial with exogenous LL-37 has been published. Grade B reflects the volume and consistency of preclinical data.

Psoriasis: Do Not Supplement (Caution)

LL-37 overexpression drives the psoriatic autoimmune cascade through the TLR9 pathway described above (Lande et al. 2007). Supplemental LL-37 risks amplifying interferon-alpha production and worsening disease.

For psoriasis patients, the focus should be on modulating (not boosting) cathelicidin activity. Psoriasis-specific dietary and natural interventions target the downstream inflammatory pathways without touching the LL-37/DNA trigger.

Lupus (Cutaneous): Do Not Supplement (Caution)

The same LL-37/DNA complex mechanism that drives psoriasis operates in cutaneous lupus erythematosus. LL-37/RNA complexes add a second trigger through TLR7. Supplementation carries the same risks as in psoriasis.

For systemic lupus, the picture is more complex. LL-37's role in SLE nephritis and systemic disease is not fully characterized. Insufficient data exists for clear guidance beyond the cutaneous presentation. Natural approaches with stronger lupus evidence include vitamin D, omega-3, and NAC.

The Vitamin D Connection

The link between vitamin D and LL-37 is not indirect or speculative. The cathelicidin gene (CAMP) contains a vitamin D response element in its promoter region. When vitamin D binds its nuclear receptor (VDR), the receptor binds directly to the CAMP promoter and activates transcription. More vitamin D means more LL-37.

Liu et al. (2006, Science) demonstrated this pathway in macrophages: vitamin D activation triggered cathelicidin production that killed intracellular Mycobacterium tuberculosis. This was a landmark finding connecting vitamin D deficiency to impaired antimicrobial defense.

For autoimmune patients, the practical implications are straightforward.

For eczema patients: Optimizing vitamin D to 40 to 60 ng/mL is the safest way to improve LL-37 status. This approach has supporting clinical data, avoids the unknowns of exogenous peptide supplementation, and addresses the documented LL-37 deficiency in atopic skin. The VITAL trial and condition-specific vitamin D studies provide an evidence foundation that direct LL-37 supplementation currently lacks.

For psoriasis patients: The vitamin D/LL-37 connection creates a nuance. Vitamin D improves psoriasis through multiple mechanisms (Treg induction, keratinocyte differentiation). The LL-37 increase from vitamin D supplementation has not been shown to worsen psoriasis, likely because the quantities induced are modest compared to the massive overexpression in psoriatic lesions. Topical vitamin D analogs (calcipotriol) are a standard psoriasis treatment. The concern about LL-37 applies to exogenous peptide supplementation, not to physiological levels induced by vitamin D.

For Crohn's patients: Vitamin D supplementation improves Crohn's outcomes in clinical data, and LL-37 induction in gut epithelium may be one mechanism. This is consistent with the broader pattern: vitamin D's autoimmune benefits may partly operate through antimicrobial peptide production at barrier surfaces.

Dosing and Administration

LL-37 has no standardized clinical dosing. No human therapeutic RCTs have been completed. What follows reflects practitioner protocols and should be discussed with a physician familiar with peptide therapy.

Subcutaneous injection: 50 to 100 mcg, two to three times per week. This is the most common route in clinical practice. Some practitioners use lower starting doses and titrate based on response.

Alternative approach: Optimize endogenous production through vitamin D supplementation (targeting serum 25(OH)D of 40 to 60 ng/mL). This is slower but better supported by clinical evidence and carries fewer unknowns.

Regulatory status: LL-37 is not FDA-approved for any therapeutic indication. It is available through research peptide vendors and some compounding pharmacies. Quality and purity vary by source.

Critical contraindication: Do not use LL-37 if you have psoriasis or cutaneous lupus. The mechanism of harm (TLR9 activation via LL-37/self-DNA complexes) is established at the molecular level. This is not a theoretical concern.

LL-37 is one of several peptides studied for autoimmune disease. BPC-157 targets gut healing through different mechanisms (VEGF, angiogenesis) without the condition-specific contraindications that LL-37 carries.

Frequently Asked Questions

Is LL-37 safe for autoimmune disease?

It depends on your condition. LL-37 may benefit eczema patients (who have documented LL-37 deficiency) and those with chronic wounds or Crohn's disease. It is contraindicated in psoriasis and cutaneous lupus, where LL-37 overexpression drives the autoimmune cascade through TLR9 activation and interferon-alpha production. This is the central fact about LL-37 that determines safety: your specific diagnosis dictates whether the peptide helps or harms.

Can LL-37 help with eczema?

The rationale is strong. Eczema patients produce insufficient LL-37 in their skin (Ong et al. 2002, NEJM), contributing to chronic S. aureus colonization and poor barrier function. Boosting LL-37 through vitamin D optimization is the safest first step, since the CAMP gene encoding LL-37 is a direct vitamin D target. Peptide supplementation has a clear mechanistic basis but no completed clinical trial.

Will LL-37 make psoriasis worse?

Potentially, yes. In psoriasis, LL-37 is already overexpressed in lesional skin. It complexes with self-DNA from damaged keratinocytes and activates plasmacytoid dendritic cells through TLR9, triggering interferon-alpha production (Lande et al. 2007, Nature Medicine). Supplemental LL-37 could amplify this cascade. Psoriasis patients should avoid LL-37 supplementation.

Does vitamin D increase LL-37 levels?

Yes. The cathelicidin gene (CAMP) is a direct transcriptional target of the vitamin D receptor. Liu et al. (2006, Science) demonstrated this pathway in human macrophages. Supplementing vitamin D to 40 to 60 ng/mL reliably increases LL-37 production in skin and gut epithelial cells. For eczema patients, this may be the safest and most evidence-supported way to correct LL-37 deficiency.

Can LL-37 help with Crohn's disease?

The mechanistic rationale is condition-specific and compelling (Grade C+). LL-37 disrupts bacterial biofilms, and adherent-invasive E. coli (AIEC) biofilms in the ileum contribute to Crohn's pathology. LL-37 is also part of the gut's innate antimicrobial defense, which is impaired in Crohn's. No Crohn's-specific LL-37 clinical studies exist, so the evidence remains mechanistic.

Where can I get LL-37 peptide?

LL-37 is available through research peptide vendors and some compounding pharmacies. It is not FDA-approved for any therapeutic indication. No standardized clinical dosing exists. Practitioner protocols typically use 50 to 100 mcg subcutaneously, two to three times per week. Quality varies by source. Always work with a physician experienced in peptide therapy, and confirm that LL-37 is appropriate for your specific condition before use.

Find out which peptides match your condition. LL-37's dual nature illustrates why autoimmune protocols must be condition-specific. What helps one condition can worsen another. Take the free 3-minute AutoimmuneFinder quiz to get an evidence-graded protocol matched to your diagnosis, severity, and current medications.

This article is for educational purposes only and does not constitute medical advice. LL-37 is not FDA-approved for any therapeutic indication. Always consult your healthcare provider before using peptide therapy or changing your treatment plan.